Exposure of the elderly to potential nephrotoxic drug combinations in Belgium
Purpose To count in the Belgian ambulatory prescription database Pharmanet, the number of elderly people treated with ACE inhibitors (ACEI) and/or angiotensine receptor blockers (ARB) (±diuretics ± β‐blockers) who eventually also received a prescription of non‐steroidal anti‐inflammatory drugs (NSAI...
Gespeichert in:
Veröffentlicht in: | Pharmacoepidemiology and drug safety 2008-10, Vol.17 (10), p.1014-1019 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose
To count in the Belgian ambulatory prescription database Pharmanet, the number of elderly people treated with ACE inhibitors (ACEI) and/or angiotensine receptor blockers (ARB) (±diuretics ± β‐blockers) who eventually also received a prescription of non‐steroidal anti‐inflammatory drugs (NSAID) or spironolactone.
Method
All prescriptions dispensed in community pharmacies are collected in the Pharmanet database. The data of 2005 were used. Two age groups were studied: 65–79 years (label 1) and 80+ years (label 2). The following chronic treatments (subgroups) were studied: (A) ACEI/ARB; (B) ACEI/ARB + diuretics; (C) ACEI/ARB + spironolactone; (D) ACEI/ARB + β‐blocker + diuretic and (E) ACEI/ARB + β‐blocker + spironolactone.
Results
In 2005, 7.3% of Belgian population was chronically treated with ACEI/ARB. Twenty‐five per cent of 65–79 year‐old‐patients (subgroup A1) and 36.15% of 80+ year‐old‐patients (subgroup A2) received ACEI/ARB. At least one package of NSAID or spironolactone was prescribed to subgroup A1 in 25.44 and 5.80%, respectively, and to subgroup A2 in 22.04 and 9.89%, respectively. In all studied subgroups and age categories, NSAID were coprecribed in more than 20–35% of cases.
Conclusions
NSAID are frequently prescribed in elderly patients treated with ACEI or ARB in combination with diuretics. Severe renal adverse effects may result in this high‐risk population. Copyright © 2008 John Wiley & Sons, Ltd. |
---|---|
ISSN: | 1053-8569 1099-1557 |
DOI: | 10.1002/pds.1641 |